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Dysregulated inﬂammation contributes to disease pathogenesis in both the periphery and the brain. Cytokines are coordinators
of inﬂammation and were originally deﬁned as secreted mediators, released from expressing cells to activate plasma membrane
receptors on responsive cells. However, a group of cytokines is now recognized as having dual functionality. In addition to their
extracellular effects, these cytokines act inside the nuclei of cytokine-expressing or cytokine-responsive cells. Interleukin-1 (IL-1)
family cytokines are key pro-inﬂammatory mediators, and blockade of the IL-1 system in inﬂammatory diseases is an attractive
therapeutic goal. All current therapies target IL-1 extracellular actions. Here we review evidence that suggests IL-1 family
members have dual functionality. Several IL-1 family members have been detected inside the nuclei of IL-1-expressing or
IL-1-responsive cells, and intranuclear IL-1 is reported to regulate gene transcription and mRNA splicing. However, further work
is required to determine the impact of IL-1 intranuclear actions on disease pathogenesis. The intranuclear actions of IL-1 family
members represent a new and potentially important area of IL-1 biology and may have implications for the future development
of anti-IL-1 therapies.
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The dual function cytokine hypothesis
Inﬂammation is required for the efﬁcient clearance of infec-
tions and repair of injured tissue, but dysregulated inﬂamma-
tion contributes to the pathogenesis of major peripheral and
central nervous system (CNS) diseases. Inﬂammation is there-
fore a current focus for drug development. Cytokines, the
coordinators of inﬂammation, were deﬁned originally as
soluble mediators, released from an expressing cell to activate
transmembrane receptors on responsive cells. However, some
cytokines are now known to have an additional set of intra-
cellular (intracrine) actions, either within the expressing cell
or following internalization by a responsive cell, and so can
be described as having dual functionality (Re, 2003).
High mobility group box 1 (HMGB1) is the prototypical
dual function cytokine. First characterized as a nuclear DNA-
binding protein that modiﬁes the interactions of transcrip-
tion factors with DNA (Thomas and Travers, 2001), HMGB1
was later found to be released actively from monocytes in
response to pro-inﬂammatory stimuli (Gardella et al., 2002).
In the periphery, released HMGB1 has pleitropic pro-
inﬂammatory effects, including action as a late mediator of
endotoxin lethality in mice (Wang et al., 1999; Lotze and
Tracey, 2005). Furthermore, in the brain, blockade of HMGB1
actions by administration of a neutralizing antibody reduces
the damage caused by cerebral ischaemia (Liu et al., 2007).
Other cytokines now reported to exhibit dual functionality
include interleukin (IL)-16 (Center et al., 2004; Wilson et al.,
2005; Zhang et al., 2008) and interferon-g (Will et al., 1996;
Ahmed et al., 2003). Dual function cytokines tend to share
certain characteristics, including cytosolic translation, non-
classical secretion and nuclear localization in cytokine
expressing cells (Cruikshank et al., 2000; Zhang et al., 2001;
Ahmed et al., 2003; Lotze and Tracey, 2005).
Interleukin-1 family cytokines are a group of key pro-
inﬂammatory mediators, implicated in the pathogenesis of
peripheral and CNS diseases, making the IL-1 system an
attractive target for therapeutic intervention. IL-1 family
cytokines are assumed to act primarily as secreted mediators,
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www.brjpharmacol.organd all current anti-IL-1 therapeutic strategies target these
extracellular IL-1 actions. However, several IL-1 family
members localize to cell nuclei and, like HMGB1, may have
dual functionality. The intranuclear actions of IL-1
family members remain a poorly understood, potentially
important area of IL-1 biology, and will be the focus of
this review.
The importance of IL-1 family cytokines in
peripheral and CNS disease
The best characterized IL-1 family members are the agonists
IL-1a (IL-1F1), IL-1b (IL-1F2), IL-18 (IL-1F4) and the naturally
occurring antagonist IL-1RA (IL-1F3, Dinarello, 1996). IL-1b is
often described as the prototypical pro-inﬂammatory cytok-
ine. Released in response to local or systemic injury or disease,
IL-1b orchestrates host defence responses. IL-1b has wide-
ranging effects on gene expression including up-regulating
cytokines, acute phase proteins and tissue remodelling
enzymes (Dinarello, 1996). As a key mediator of innate immu-
nity, IL-1b is a potent pyrogen (Murakami et al., 1990) and
stimulates neutrophilia and the inﬁltration of circulating leu-
kocytes into inﬂamed tissues (Pettipher et al., 1986; Ulich
et al., 1987). IL-1b also plays an important role in the adaptive
immune response by stimulating the development of acti-
vated lymphocytes (Gery et al., 1972).
In the periphery, IL-1b is required for the efﬁcient clearance
of bacterial infections (Miller et al., 2007). However, IL-1b is
also implicated in the pathogenesis of many acute and
chronic peripheral diseases. For example, excessive acute acti-
vation of the IL-1b system contributes to the multi-organ
failure caused by sepsis (Cohen, 2002). Chronic overproduc-
tion of IL-1b is crucial in the familial periodic fever syndromes
(Church et al., 2008) and can contribute to the growth, vas-
cularization and metastasis of malignant tumours (Voronov
et al., 2003; Elaraj et al., 2006; Krelin et al., 2007). In addition,
chronically elevated IL-1b levels are implicated in the patho-
genesis of rheumatoid arthritis (Kay and Calabrese, 2004) and
chronic obstructive pulmonary disease (Chung, 2001).
Endogenous IL-1b expression in the healthy brain is very
low (Vitkovic et al., 2000). The majority of central IL-1b
actions occur in the context of neuroinﬂammation, which
leads to an up-regulation of IL-1b expression by microglia, the
resident CNS macrophage population (Pearson et al., 1999;
Vezzani et al., 1999; De Simoni et al., 2000; Mabuchi et al.,
2000). Enhanced IL-1b expression is observed in many acute
and chronic neurodegenerative diseases, and IL-1b polymor-
phisms are linked to altered susceptibility to these diseases
(Allan et al., 2005).
The importance of IL-1b in brain injury caused by cerebral
ischaemia has been ﬁrmly established in animals. Adminis-
tering exogenous IL-1b exacerbates damage caused by focal
cerebral ischaemia in rodents (Yamasaki et al., 1995; Loddick
and Rothwell, 1996). Blockade of the IL-1b system with a
caspase-1 (an IL-1b processing enzyme) inhibitor, IL-1RA, or a
neutralizing antibody for IL-1b, also reduces this damage in
rats (Relton and Rothwell, 1992; Yamasaki et al., 1995; Ross
et al., 2007). In addition, deletion of the genes for both IL-1a
and b, or of caspase-1, substantially reduces ischaemic brain
damage in mice, whereas deletion of IL-1RA enhances damage
(Schielke et al., 1998; Boutin et al., 2001; Pinteaux et al.,
2006).
Interleukin-1b is far more widely studied than IL-1a (there
are more than 31 000 papers in the Pubmed database, http://
www.ncbi.nlm.nih.gov/sites/entrez, on IL-1b, in comparison
with less than 9000 on IL-1a, using the following keyword
search: ‘IL-1alpha/beta’ OR ‘IL-1 alpha/beta’ OR ‘Interleukin-
1alpha/beta’ OR ‘Interleukin-1 alpha/beta’). This may be due
to an assumption that as both cytokines bind and activate the
same receptor, they are likely to have redundant effects in vivo
(Dinarello, 1997). However, comparison of IL-1a- and IL-1b-
deﬁcient mice reveals that these cytokines have non-
redundant roles in host defence and disease pathogenesis.
Tumorigenesis, turpentine-induced fever and defence against
bacterial infection are all dependent on IL-1b but not IL-1a
(Horai et al., 1998; Krelin et al., 2007; Miller et al., 2007). In
contrast, diet-induced weight gain and atherosclerosis are
IL-1a- and not IL-1b-dependent (Kamari et al., 2007). T cell-
dependent antibody production is IL-1b-dependent, but the
activation of T cells in response to contact allergens is IL-1a-
dependent (Nakae et al., 2001a; Nakae et al., 2001b). In addi-
tion, IL-1a and b have different, complementary roles in host
defence against Candida albicans infection (Vonk et al., 2006).
Different patterns of IL-1a and b expression, processing and
release (Lonnemann et al., 1989; Fenton, 1992; Hacham et al.,
2000) may all be important in explaining the non-redundant
effects of these two cytokines. In addition, as discussed below,
theintranuclearactionsofIL-1aandbarelikelytobedifferent.
Recently, a further seven IL-1 family ligands (IL-1F5-F11)
have been identiﬁed through sequence homology (Dunn
et al., 2001; Schmitz et al., 2005). IL-33 (IL-1F11) acts as an
immunomodulator, promoting TH2-type immune responses,
and is implicated in the pathogenesis of asthma, rheumatoid
arthritis and cardiovascular disease (Kakkar and Lee, 2008).
The roles of IL-1F5-10 in host defence and disease pathogen-
esis remain poorly understood.
IL-1 family members as released mediators
Interleukin-1 family members are commonly assumed to act
primarily following release from IL-1 producing cells, via
binding transmembrane IL-1 receptors on responsive cells.
Mechanisms of IL-1a and b processing and release, and acti-
vation of the classical IL-1 signalling pathway on responsive
cells, have been reviewed extensively elsewhere, (Nickel,
2003; Prudovsky et al., 2003; Mariathasan and Monack, 2007;
Brikos and O’Neill, 2008) and are summarized here (see
Figure 1).
Interleukin-1a and b are unusual secreted proteins, in that
they are translated in the cytosol, and have no signal
sequence to direct them through the endoplasmic reticulum
(ER)-Golgi classical pathway of secretion (Rubartelli et al.,
1990; Stevenson et al., 1992). Pro-IL-1b (31 kD) is cleaved to
release the active 17 kD mature protein by caspase-1 (Thorn-
berry et al., 1992). Caspase-1 activity is regulated by NOD-like
receptors, a family of intracellular pattern recognition recep-
tors that detect pathogen- and damage-associated molecular
patterns including gout-associated uric acid crystals, cytosolic
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Muruve et al., 2008). NOD-like receptor activation leads to
oligomerization and recruitment of caspase-1 to a multimeric
inﬂammasome complex, facilitating caspase-1 activation by
autoproteolysis (Mariathasan and Monack, 2007).
Pro-IL-1a (31 kD) is released on cell death and, in contrast
to pro-IL-1b, can activate IL-1 receptors (Mosley et al., 1987).
Pro-IL-1a can also be cleaved by calpains (calcium-dependent
proteases, Kobayashi et al., 1990). Heat shock, calcium iono-
phores and ATP all stimulate the release of mature IL-1a
in vitro (Watanabe and Kobayashi, 1994; Perregaux and Gabel,
1998; Mandinova et al., 2003). However, IL-1a release from
monocytes is less efﬁcient than IL-1b release in vitro (Lonne-
mann et al., 1989; Rubartelli et al., 1990), and in vivo many
consider IL-1a to be a predominantly intracellular cytokine
released only on cell death during severe disease (Dinarello,
1996). This view is supported by the detection of IL-1a-
neutralizing autoantibodies in a substantial proportion of
healthy humans (5–28%, Saurat et al., 1991; Miossec, 2002).
In these individuals, IL-1a-reactive B-cells have evaded immu-
nological tolerance mechanisms that would normally lead to
the depletion or inactivation of self antigen-reactive B-cells
(Singh and Schwartz, 2006). One explanation for this failure
to develop proper immune tolerance to IL-1a is that during
immune cell development, IL-1a is retained intracellularly,
and so not available extracellularly for identiﬁcation as a self
antigen.
Extracellular IL-1a and b bind and activate the single trans-
membrane domain type I IL-1 receptor (IL-1RI) on responsive
cells (Vigers et al., 1997). Pro-IL-1a, mature IL-1a and mature
IL-1b all bind IL-1RI with similar afﬁnity (KD = 1–10 nM)
(Dower et al., 1986; Mosley et al., 1987; McMahan et al.,
1991). This triggers IL-1 receptor accessory protein (IL-1RAcP)
binding to the IL-1RI/IL-1a/b complex (Wesche et al., 1997). A
multi-protein signalling complex is then recruited to the
active receptor heterodimer. This signalling complex ulti-
mately activates mitogen-activated protein kinases and
nuclear factor kB (NFkB), and so stabilizes mRNA and regu-
lates gene transcription [reviewed in Brikos and O’Neill
(2008)]. A more rapid IL-1RI/IL-1RAcP-dependent IL-1b sig-
nalling pathway has been observed recently in neurones
(Viviani et al., 2003; Davis et al., 2006). IL-1b induces changes
in neuronal ﬁring rates through neutral sphingomyelinase
activation, and downstream Src kinase-mediated phosphory-
lation of the NMDA receptor subunit NR2B (Viviani et al.,
2003). This rapid signalling pathway is implicated in the
febrile response to IL-1b (Sanchez-Alavez et al., 2006).
Interleukin-1RA and IL-1RII are both negative regulators of
IL-1a/b signalling. IL-1RA is a competitive antagonist at
IL-1RI, which binds to IL-1RI but fails to recruit IL-1RAcP and
activate signal transduction (Sims, 2002). IL-1RII acts as a
decoy receptor, binding IL-1a and b without activating sig-
nalling (Colotta et al., 1993; Rauschmayr et al., 1997). As with
IL-1 family ligands, there are a number of newly identiﬁed
Figure 1 IL-1 family members as released mediators. IL-1a and b, the two best characterized IL-1 family agonists, are translated in the
cytoplasm as 31 kD pro-forms. Pro-IL-1a and b are then proteolytically cleaved by calpain and caspase-1, respectively, to produce the mature
proteins. Caspase-1 is activated by recruitment to multimeric inﬂammasomes, enhancing caspase-1 autoproteolysis. Pro-IL-1a, mature IL-1a
and mature IL-1b can all be released from cells and bind to transmembrane IL-1RI (RI) on IL-1-responsive cells. This leads to the recruitment
of IL-1RAcP (AcP) to IL-1RI. A multi-protein complex is recruited to the cytoplasmic domain of the receptor dimer, leading to the activation of
NFkB and mitogen-activated protein kinases, and to changes in gene expression and RNA stability. IL-1RA, the best developed anti-IL-1
therapeutic agent, acts as a competitive antagonist, binding IL-1RI but failing to recruit IL-1RAcP and activate signal transduction. IL-1,
interleukin-1; IL-1RA, IL-1 receptor antagonist; IL-1RI, type I IL-1 receptor; IL-1RAcP, IL-1 receptor accessory protein; NFkB, nuclear factor kB.
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known to bind new IL-1 family ligands (IL-1F5-F11), while
others remain orphan receptors.
Current anti-IL-1 therapeutic strategies
The importance of IL-1a and b in the pathogenesis of periph-
eral and CNS diseases makes the IL-1 system an attractive
therapeutic target (Ledford, 2007). The best developed anti-
IL-1 therapy is IL-1RA, the naturally occurring antagonist that
competes with IL-1a and b for IL-1RI. IL-1RA is approved for
the treatment of rheumatoid arthritis in the USA (Kay and
Calabrese, 2004) and is currently being developed as a treat-
ment for stroke (Emsley et al., 2005). However, IL-1RA has a
short plasma half-life and relatively poor brain penetration, so
novel anti-IL-1 therapies are still being investigated [reviewed
in Braddock and Quinn (2004)]. These new therapies all target
the extracellular actions of IL-1a and b, either by inhibiting
IL-1b processing and release or by reducing the bioavailability
of IL-1a and b in the extracellular space. However, several IL-1
family members localize to cell nuclei and may regulate intra-
nuclear processes such as transcription and RNA splicing.
There follows a review of the evidence for intranuclear roles
of IL-1 family members (summarized in Figure 2) and the
potential implications for future development of anti-IL-1
therapeutics.
Intranuclear actions of IL-1a
The most widely reported intranuclear IL-1 family member is
IL-1a. Experiments conducted prior to elucidation of the IL-1
classical signalling pathway indicated that radiolabelled IL-1a
was internalized and localized to the nucleus of a number of
IL-1-responsive cell lines (Mizel et al., 1987; Grenfell et al.,
1989; Curtis et al., 1990; Weitzmann and Savage, 1992). Later,
it was shown that IL-1 internalization and nuclear localiza-
tion were not necessary for classical signalling through IL-1RI
(Heguy et al., 1991). However, whether IL-1a endocytosis and
nuclear localization have any other role (independent of the
classical signalling pathway) has not been investigated
further.
Intranuclear IL-1a has also been observed in IL-1a express-
ing cells (see Table 1). The nuclear entry of cytosolic proteins
is regulated by the nuclear pore complex (NPC), a large multi-
protein complex spanning the nuclear membrane, which
allows free diffusion of proteins smaller than ~50 kD (Paine,
1975; Peters, 1984; Fahrenkrog and Aebi, 2003). Larger
nuclear proteins contain one of a range of nuclear localization
sequence (NLS) motifs, including the canonical NLS, a short,
positively charged sequence of amino acids, allowing their
interaction with the nuclear import apparatus. The NLS is
bound by cytosolic importins, which facilitate transport
across the NPC [reviewed in Stewart (2007)]. This process is
driven by gradients of the GDP- and GTP-bound forms of the
small GTPase Ran across the nuclear membrane (Izaurralde
et al., 1997).
Both pro-IL-1a and b are small enough (31 kD) to diffuse
passively across the NPC. However, Wessendorf et al. (1993)
made the surprising discovery that the pro-piece of IL-1a
(ppIL-1a) contains a canonical NLS, able to target a
b-galactosidase fusion protein to the nucleus. Since this dis-
covery of the IL-1a NLS, nuclear localization of pro-IL-1a and
ppIL-1a has been reported both in transfected cells and in
cells endogenously expressing IL-1a (see Table 1). Indeed
Figure 2 Interleukin (IL)-1 intranuclear actions. (A) Pro-IL-1a and the IL-1a pro-piece (ppIL-1a) are actively imported into the nucleus from
the cytosol. Intranuclear pro- and ppIL-1a regulate gene expression through binding histone acetyl transferases (HATs), IL-1RII, HAX-1 and
necdin. ppIL-1a also regulates RNA splicing through binding RNA splicing proteins. Changes in gene expression and RNA splicing may be
responsible for the intranuclear effects of pro- and ppIL-1a on cell migration, proliferation and apoptosis (broken lines). (B) Pro-IL-1b diffuses
passively into cell nuclei, but no intranuclear actions of pro-IL-1b have been reported. IL-33 and IL-1F7b can also enter cell nuclei. Intranuclear
IL-33 and IL-1F7b are reported to repress transcription, but the mechanisms involved remain poorly deﬁned.
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of these cell types.
Intranuclear IL-1a is reported to regulate cell proliferation,
migration and gene expression (summarized in Table 2).
These IL-1a effects have been observed mainly in IL-1a-
overexpressing cells and are not inhibited by blockade of
extracellular IL-1a actions (using IL-1RA or neutralizing anti-
bodies). The lack of effect of exogenous IL-1a has also been
used to exclude involvement of extracellular IL-1a. In some
cases, an intranuclear site of action for IL-1a has been more
convincingly demonstrated by IL-1a NLS mutagenesis.
However, confusion remains as to whether pro-IL-1a or
ppIL-1a is the active isoform, the nature of IL-1a intranuclear
actions, and the molecular mechanisms through which IL-1a
exerts intranuclear effects.
The confusion surrounding the nature of the intranuclear
effects of IL-1a is well demonstrated by the various reported
roles of intranuclear IL-1a isoforms on cell proliferation. In
endothelial cell lines and a human osteosarcoma cell line
(SaOS-2), overexpression of pro-IL-1a inhibits cell prolifera-
tion (Maier et al., 1994; Palmer et al., 2005). In addition, in
HEK-293 (human embryonic kidney cell line) cells and cancer
cell lines, overexpression of intranuclear ppIL-1a causes apo-
ptosis (Pollock et al., 2003). However, in other cell types IL-1a
appears to promote cell proliferation. Endogenous expression
of pro-IL-1a in ﬁbroblasts promotes ﬁbroblast proliferation in
systemic sclerosis (SSc) (Kawaguchi et al., 2004; Abraham and
Varga, 2005). Furthermore, in perivascular mesangial cells,
ppIL-1a overexpression causes malignant transformation,
suggesting a role for ppIL-1a as an oncoprotein (Stevenson
et al., 1997). In vascular smooth muscle cells, intranuclear
pro-IL-1a and ppIL-1a have no effect on proliferation (Beasley
and Cooper, 1999). Some of the variables that may explain
the contradictory results observed include cell type, IL-1a
isoform (pro- vs. ppIL-1a) and expression system (endog-
enous expression, stable or transient transfection). The role of
endogenous intranuclear IL-1a in regulating cell proliferation
in vivo remains unknown.
Intranuclear pro-IL-1a may also regulate cell migration
(McMahon et al., 1997; Merhi-Soussi et al., 2005). However,
these two papers report opposite effects of pro-IL-1a on cell
migration rates, perhaps reﬂecting differences in the cell
migration assay used (migration following culture wounding
vs. migration across a transwell membrane).
The most consistently reported effects of intranuclear IL-1a
are on gene expression. In HEK-293 cells, and in murine
and human ﬁbroblasts, pro-IL-1a overexpression enhances
expression of the pro-inﬂammatory cytokine IL-6 and/or the
chemokine IL-8 (Kawaguchi et al., 2004; Werman et al., 2004;
Cheng et al., 2008). In endothelial cells, pro-IL-1a overexpres-
sion enhances interferon-g- or tumour necrosis factor
a-induced macrophage inhibitory protein 2 expression
(Werman et al., 2004). Endothelial cell ppIL-1a overexpres-
sion also enhances endogenous IL-1a gene expression, indi-
cating that an intracrine positive feedback loop may operate
in these cells (Werman et al., 2004). Endogenous IL-1a has
similar intranuclear effects on gene expression. In SSc
ﬁbroblasts, endogenous pro-IL-1a enhances IL-6 and collagen
Table 1 The nuclear localization of IL-1 in IL-1-expressing cells
Cell type/stimulus IL-1 isoform IL-1 nuclear localization References
Overexpression
NIH-3T3 cells pro-IL-1a +++ Wessendorf et al. (1993)
ppIL-1a +++
Endothelial cell line pro-IL-1a +++ Maier et al. (1994)
Mature IL-1a-
Perivascular mesangial cells pro-IL-1a- Stevenson et al. (1997)
ppIL-1a +++
HEK-293 ppIL-1a +++ Pollock et al. (2003)
NIH-3T3 pro-IL-1a +++ Werman et al. (2004)
SaOS-2 pro-IL-1a +++ Palmer et al. (2005)
NIH-3T3 pro-IL-1a+ Sudo et al. (2005)
ppIL-1a +++
HEK-293 pro-IL-1a +++ Cheng et al. (2008)
COS-7 pro-IL-1a +++ Luheshi et al. (2009)
pro-IL-1b+
Endogenous expression
Lipid A-treated human mesangial cells pro-IL-1a+ + Stevenson et al. (1992)
pro-IL-1b +++
Untreated brown adipose tissue cells pro-IL-1a +++ Burysek and Houstek (1996)
Mature IL-1a +++
Systemic sclerosis ﬁbroblasts pro-IL-1a +++ Kawaguchi et al. (2004)
Untreated vascular smooth muscle cells pro-IL-1a +++ Schultz et al. (2007)
Chlamydia trachomatis-infected HeLa cells pro-IL-1a +++ Cheng et al. (2008)
LPS-treated microglia pro-IL-1a +++ Luheshi et al. (2009)
pro-IL-1b+
Summary of studies reporting nuclear localization of IL-1a and b isoforms, either when overexpressed (transient or stable transfection) or when expressed
endogenously. +++, ++, + and - indicate the level of nuclear IL-1 relative to cytosolic IL-1, with +++ indicating a predominantly intranuclear distribution and - an
exclusively cytosolic distribution. IL-1 nuclear localization was assessed by cell fractionation, immunocytochemistry and imaging of ﬂuorescent tagged IL-1 fusion
proteins.
HEK-293, human embryonic kidney cell line; HeLa, human cervical epithelial cell line; IL-1, interleukin-1; NIH-3T3, murine ﬁbroblast cell line; ppIL-1a,I L - 1 a
pro-piece; SaOS-2, human osteosarcoma cell line.
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trachomatis-infected HeLa (human cervical epithelial cell line)
cells, endogenous pro-IL-1a regulates IL-8 expression (Cheng
et al., 2008).
The mechanism by which intranuclear IL-1a regulates gene
expression remains unclear. Pro- and ppIL-1a bind histone
acetyl transferases (Buryskova et al., 2004), multifunctional
enzymes that can regulate transcription by modifying chro-
matin structure and acetylating transcription factors such as
NFkB (Chan and La Thangue, 2001; Chen et al., 2001). This
interaction may explain how pro- and ppIL-1a can transacti-
vate gene expression of a Gal-4 reporter when fused to the
Gal-4 DNA-binding domain, and can directly activate NFkB-
and activator protein-1-dependent transcription (Buryskova
et al., 2004; Werman et al., 2004). ppIL-1a also interacts with
necdin (an intranuclear suppressor of growth and collagen
production), HAX-1 (HS1-associated protein X-1, a ubiqui-
tously expressed protein with poorly deﬁned functions) and
intranuclear IL-1RII (Yin et al., 2001; Hu et al., 2003; Kawagu-
chi et al., 2006). These interactions are implicated in the intra-
nuclear effects of pro-IL-1a on cell proliferation and gene
expression in SSc ﬁbroblasts (Hu et al., 2003; Kawaguchi et al.,
2006).
In contrast to these reports that intranuclear IL-1a regulates
transcription, Pollock et al. (2003) argue that regulation of
RNA splicing underlies the pro-apoptotic effects of ppIL-1a.
ppIL-1a localizes to nuclear speckles [storage sites for RNA
splicing proteins, reviewed in Lamond and Spector (2003)]
and not transcription sites in HEK-293 cells. Pollock et al.
(2003) demonstrate that ppIL-1a interacts with various RNA
splicing proteins, and that a point mutation blocking this
interaction inhibits the pro-apoptotic effects of ppIL-1a.
ppIL-1a overexpression caused a shift in the alternative
splicing of the apoptosis regulatory gene Bcl-X (B-cell
lymphoma-X) from the anti-apoptotic Bcl-XL to the pro-
apoptotic Bcl-XS isoform, suggesting a mechanism by which
this ppIL-1a interaction may promote apoptosis.
To conclude, the most convincing evidence thus far is for a
role in regulating gene expression, possibly through an inter-
action with histone acetyl transferases. Cell-speciﬁc differ-
ences in the expression and activation of other transcription
and splicing factors would help explain the model-dependent
impact of intranuclear pro-IL-1a on the expression of speciﬁc
genes, and on cell proliferation and migration. However,
investigations into the roles of intranuclear IL-1a have
remained focused on cell lines overexpressing IL-1a. The
question remains as to whether similar or entirely novel IL-1a
nuclear effects occur in cells expressing endogenous IL-1a
in vivo.
icIL-1RA isoforms: regulators of IL-1a
intranuclear actions?
Unlike IL-1a and IL-1b, secreted IL-1RA (sIL-1RA, a 17 kD
protein variably glycosylated to produce a 22–25 kD protein)
has an N-terminal signal sequence that directs its trafﬁcking
and secretion through the ER-Golgi. However, three intracel-
lular isoforms of IL-1RA (icIL-1RA 1–3) have been identiﬁed
that lack this signal sequence and remain intracellular
[reviewed in Arend (2002)]. icIL-1RA1 and icIL-1RA2 are gen-
erated from alternative transcriptional start sites on the
IL-1RA gene. Either one (icIL-1RA1, 18 kD) or two (icIL-1RA2,
25 kD) 5′ exons are transcribed and spliced into an internal
splice acceptor site within the ﬁrst exon of sIL-1RA (Haskill
et al., 1991; Muzio et al., 1995). icIL-1RA3 (16 kD) is a trun-
cated variant of sIL-1RA, created either by alternative transla-
tional initiation or alternative splicing (Malyak et al., 1998).
The potential actions of these intracellular isoforms remain
poorly deﬁned and may be separated into three categories.
First, they may be released (Corradi et al., 1995; Levine et al.,
1997; Muzio et al., 1999; Wilson et al., 2004; Evans et al.,
2006) and act as competitive antagonists for IL-1RI, in a
similar manner to sIL-1RA. Recombinant icIL-1RA1 has a
similar afﬁnity to sIL-1RA for IL-1RI, whereas icIL-1RA3 has
a four- to ﬁvefold lower afﬁnity and so is less likely to act in
this way (Malyak et al., 1998). Second, icIL-1RA isoforms
expressed in IL-1-responsive cells may antagonize IL-1a- and
b-induced signalling through IL-1RI by an intracellular
mechanism (Watson et al., 1995; Garat and Arend, 2003;
Banda et al., 2005). Banda et al. (2005) report that icIL-1RA1
interacts with the COP9 signalsome, inhibits COP9
signalsome-associated kinases, and so inhibits cytokine gene
expression induced by exogenously applied IL-1a in kerati-
nocyte cell lines. Third, icIL-1RA could antagonize the intra-
nuclear actions of IL-1a. For example, Merhi-Soussi et al.
(2005) found that stably co-transfecting icIL-1RA1 with either
pro-IL-1a or ppIL-1a blocked the effects of pro- or ppIL-1a on
cell migration. Pro-IL-1a can regulate icIL-1RA1 gene expres-
sion via an intracellular mechanism, suggesting a negative
feedback loop to preventing excessive pro-IL-1a intranuclear
action (Higgins et al., 1999). The three intracellular isoforms
of IL-1RA may thus have intracellular actions, and in
particular may alter the intranuclear actions of IL-1a in
IL-1a-expressing cells.
Intranuclear IL-1b, IL-33 and IL-1F7b
Pro-IL-1b, in contrast to pro-IL-1a, is commonly viewed as a
cytosolic and extracellular cytokine, despite early reports
showing the nuclear localization of pro-IL-1b in lipid
A-stimulated mesangial cells (Stevenson et al., 1992), and the
internalization and nuclear localization of radiolabelled IL-1b
by ﬁbroblasts (Qwarnstrom et al., 1988). We have recently
found that endogenously expressed pro-IL-1b is intranuclear
in cultured microglia (Luheshi et al., 2009). In contrast to
pro-IL-1a, pro-IL-1b enters cell nuclei by passive diffusion
(Luheshi et al., 2009). Whether pro-IL-1b is intranuclear in
other cell types remains unknown.
Many pro-IL-1a intranuclear actions reported in the litera-
ture are dependent on ppIL-1a, which shares little sequence
homology with ppIL-1b (Maier et al., 1994; McMahon et al.,
1997; Stevenson et al., 1997; Pollock et al., 2003; Werman
et al., 2004; Merhi-Soussi et al., 2005). In addition, ppIL-1b
fails to reproduce the apoptosis-promoting effects of intra-
nuclear ppIL-1a (Pollock et al., 2003). These reports support
the hypothesis that pro-IL-1b does not have the same
intranuclear actions as pro-IL-1a. Whether pro-IL-1b has no
Dual function IL-1 family cytokines
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nuclear actions, remains unknown.
Of the newly identiﬁed IL-1 family cytokines, IL-33 (also
known as IL-1F11) and IL-1F7b both localize to the nucleus of
expressing cells (Carriere et al., 2007; Sharma et al., 2008).
IL-1F7b nuclear localization in an overexpressing macrophage
cell line correlates with the inhibition of LPS-induced cytok-
ine gene expression (Sharma et al., 2008). IL-33 interacts with
chromatin and shows transcriptional repressor activity when
overexpressed in cell lines (Carriere et al., 2007). Intranuclear
IL-33 is found in resting endothelial cells in vivo, and expres-
sion is down-regulated on endothelial activation by pro-
inﬂammatory or angiogenic stimuli (Kuchler et al., 2008;
Moussion et al., 2008). This has led some to suggest that
transcriptional repression by intranuclear IL-33 helps main-
tain endothelial cells in a resting state (Kuchler et al., 2008).
Future directions: implications of IL-1 family
cytokine dual functionality for future development
of anti-IL-1 therapeutics
Thus, in addition to their extracellular effects, several IL-1
family members appear to have intranuclear actions.
However, the nature and in vivo consequences of IL-1 family
intranuclear actions remain unclear.
The intranuclear mechanisms of action for IL-1a, IL-33,
IL-1F7b (and potentially IL-1b) remain poorly described. The
most widely studied intranuclear IL-1 family member, IL-1a,
appears to regulate gene transcription and RNA splicing.
However, further investigation is required into the protein–
protein interactions involved in these intranuclear IL-1a
actions. In addition, the mechanisms by which IL-1F7b and
IL-33 repress transcription remain unknown, and whether
IL-1b has any intranuclear effects similarly remains unclear.
Further investigation is also required into the role of IL-1
family member intranuclear actions in vivo. Intranuclear
HMGB1 is expressed constitutively in almost all eukaryotic
cells, and HMGB1 deﬁciency is lethal in mice due to the
importance of HMGB1 intranuclear actions in development
and homeostasis (Calogero et al., 1999).
In contrast to HMGB1, IL-1a and b expression tends to be
low in healthy tissues and enhanced by infection or injury
(Ulich et al., 1990; Clark et al., 1991). Furthermore, IL-1a- and
b-deﬁcient animals develop normally in the absence of an
immune challenge (Horai et al., 1998). Thus, intranuclear
IL-1a and b actions, like their extracellular actions, are likely
to contribute to inﬂammation during host defence responses
or disease pathogenesis. Based on the in vitro studies described
above, intranuclear IL-1a may promote abnormal prolifera-
tion and excessive collagen production by SSc ﬁbroblasts,
contributing to the extensive ﬁbrosis that characterizes the
ﬁnal pathology of this disease (Kawaguchi et al., 2004;
Abraham and Varga, 2005; Kawaguchi et al., 2006). However,
in vivo evidence to support a role of intranuclear IL-1a or b in
any disease is lacking, and identiﬁcation of conditions under
which IL-1a and b localize to cell nuclei in vivo may help
identify the potential inﬂuence of these intranuclear cytok-
ines on disease progression.
The detection of intranuclear IL-33 in resting endothelial
cells indicates that this IL-1 family member may, like HMGB1,
play a role in homeostasis (Kuchler et al., 2008; Moussion
et al., 2008). However, like IL-1a and b, expression of IL-33
can be induced by pro-inﬂammatory stimuli (Schmitz et al.,
2005; Xu et al., 2008). Whether IL-33 is intranuclear under
these conditions remains unknown.
Interleukin-1 family members are key pro-inﬂammatory
cytokines whose extracellular actions are implicated in the
pathogenesis of major peripheral and CNS diseases. Current
anti-IL-1 therapy is limited to blockade of these extracellular
actions. The more recently discovered intranuclear actions of
IL-1 family members reviewed here suggest that these cytok-
ines should be considered as dual function mediators. This
dual functionality of cytokines represents a novel and poten-
tially biologically important area of cytokine biology. Further
investigation will clearly be required to determine the precise
nature and importance of IL-1 family intranuclear actions in
disease and to assess the therapeutic implications of these
intranuclear actions. This could lead to the identiﬁcation of
novel therapeutics to treat inﬂammatory diseases.
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